Evidence map›Paper›PMID 40866511›Full record

ArticleScientific reports2025

Evaluation of teicoplanin protein-binding variability and clinical utility of its free serum concentration measurement.

Yoshitaka Inno, Takanori Taogoshi, Airi Matsumoto, Tomoharu Yokooji, Hiroaki Matsuo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yoshitaka InnoDepartment of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Takanori TaogoshiDepartment of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Airi MatsumotoSchool of Pharmaceutical Sciences, Hiroshima University, Hiroshima, Japan.
Tomoharu YokoojiDepartment of Frontier Science for Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroaki MatsuoDepartment of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. hmatsuo@hiroshima-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of teicoplanin (TEIC) therapy based on its free serum concentrations may be crucial for optimizing efficacy and safety. This study investigated the protein-binding variability of TEIC and evaluated predictive models for free TEIC concentrations in patients with various diseases. Additionally, effects of free serum TEIC concentrations on the efficacy and adverse event risk of TEIC therapy were analyzed. Free TEIC concentrations in sera from patients received TEIC treatment were determined via high-performance liquid chromatography followed by ultrafiltration. Therapeutic efficacy was evaluated by monitoring the changes in the serum C-reactive protein levels and fever, and adverse events were evaluated by examining the renal and hepatic functions. No significant correlation was observed between serum albumin concentration and free TEIC percentage; however, free TEIC percentage showed significant interpatient variability. Notably, predictive models based on the serum albumin and total serum TEIC concentrations were inaccurate for patients with different diseases. However, measured free serum TEIC concentrations predicted the therapeutic efficacy and the adverse event risk. In conclusion, our results suggest that TEIC dosage management based on the measured free serum TEIC concentrations, rather than the total or estimated TEIC concentrations, improves the clinical outcomes of patients with methicillin-resistant Staphylococcus aureus infections.

Indexed as

Anti-Bacterial AgentsStaphylococcal InfectionsTeicoplaninAdultAgedC-Reactive ProteinFemaleHumansMaleMethicillin-Resistant Staphylococcus aureusMiddle AgedProtein BindingSerum AlbuminAnti-Bacterial AgentsC-Reactive ProteinSerum AlbuminTeicoplaninAdverse eventsEfficacyFree serum concentrationSerum albumin concentrationTeicoplanin

Identifiers

PMID40866511
PMCPMC12391519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.